Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies

BACKGROUND: Talazoparib (BMN673) is a new poly(ADP-ribose) polymerase inhibitor that has been FDA approved for patients suffering from metastatic breast cancer with germline BRCA mutations. METHOD AND RESULTS: In the current study, an accurate and efficient liquid chromatography-tandem mass spectrom...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W, Kadi, Adnan A, Abdelhameed, Ali S, Alhazmi, Hassan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049284/
https://www.ncbi.nlm.nih.gov/pubmed/32158196
http://dx.doi.org/10.2147/DDDT.S239458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049284/
https://www.ncbi.nlm.nih.gov/pubmed/32158196
http://dx.doi.org/10.2147/DDDT.S239458

Ejemplares similares